Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis

European Journal of Clinical Investigation

Volumn 45, Issue 3, 2015, Pages 274-287

  da Silva, Analina R ^a   Fraga Silva, Rodrigo A ^b   Stergiopulos, Nikolaos ^b   Montecucco, Fabrizio ^a,c,d   Mach, François ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b EPFL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Acute coronary syndromes; Angiotensin; Atherosclerosis

Indexed keywords

ANGIOTENSIN; CAPTOPRIL; ENALAPRIL; LOSARTAN; RAMIPRIL; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOGENESIS; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; HUMAN; INFLAMMATION; MEDLINE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANTAGONISTS AND INHIBITORS; ARTERITIS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY; PLAQUE, ATHEROSCLEROTIC; RUPTURE, SPONTANEOUS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; APOPTOSIS; ARTERITIS; BIOMARKERS; CELL PROLIFERATION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RUPTURE, SPONTANEOUS;

EID: 84923457154     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12401     Document Type: Review

References (149)

1. Deckers JW. Classification of myocardial infarction and unstable angina: a re-assessment. Int J Cardiol 2013;167:2387-90.
2. Thygesen KA, Alpert JS. The definitions of acute coronary syndrome, myocardial infarction, and unstable angina. Curr Cardiol Rep 2001;3:268-72.
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129:e28-292.
4. Chen SY, Crivera C, Stokes M, Boulanger L, Schein J. Clinical and economic outcomes among hospitalized patients with acute coronary syndrome: an analysis of a national representative Medicare population. Clinicoecon Outcomes Res 2013;5:181-8.
5. Inagami T. A memorial to Robert Tiegerstedt: the centennial of renin discovery. Hypertension 1998;32:953-7.
6. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.
7. Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res 2002;35:1001-15.
8. Chung O, Kuhl H, Stoll M, Unger T. Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int Suppl 1998;67:S95-9.
9. Matsusaka T, Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol 1997;59:395-412.
10. McGraw AP, Bagley J, Chen WS, Galayda C, Nickerson H, Armani A et al. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J Am Heart Assoc 2013;2:e000018.
11. Newfell BG, Iyer LK, Mohammad NN, McGraw AP, Ehsan A, Rosano G et al. Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways. Arterioscler Thromb Vasc Biol 2011;31:1871-80.
12. Zhang X, Liu J, Pang X, Zhao J, Wang S, Wu D. Aldosterone induces C-reactive protein expression via MR-ROS-MAPK-NF-κB signal pathway in rat vascular smooth muscle cells. Mol Cell Endocrinol 2014;395:61-8.
13. Mignano A, Pitruzzella V, Arnone G, Arnone MT, Rotolo A, Assennato P et al. Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. J Cardiovasc Med (Hagerstown) 2014;15:27-32.
14. Akishita M, Iwai M, Wu L, Zhang L, Ouchi Y, Dzau VJ et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 2000;102:1684-9.
15. Lemarie CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010;11:19-31.
16. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-57.
17. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14:1738-47.
18. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation 2006;113:1353-60.
19. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:E1-9.
20. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000;275:33238-43.
21. Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 2006;350:1026-31.
22. Snyder RA, Watt KW, Wintroub BU. A human platelet angiotensin I-processing system. Identification of components and inhibition of angiotensin-converting enzyme by product. J Biol Chem 1985;260:7857-60.
23. Santos RA, Brosnihan KB, Chappell MC, Pesquero J, Chernicky CL, Greene LJ et al. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 1988;11(2 Pt 2):I153-7.
24. Schiavone MT, Santos RA, Brosnihan KB, Khosla MC, Ferrario CM. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A 1988;85:4095-8.
25. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27.
26. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003;100:8258-63.
27. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 2013;216:R1-17.
28. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 2008;93:519-27.
29. Ferreira AJ, Bader M, Santos RA. Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review. Expert Opin Ther Pat 2012;22:567-74.
30. Jankowski V, Vanholder R, van der Giet M, Tolle M, Karadogan S, Gobom J et al. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 2007;27:297-302.
31. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F et al. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 2013;112:1104-11.
32. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006;98:121-8.
33. -/- mice. Hypertension 2004;44:277-82.
34. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276-82.
35. Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol 2001;16:285-92.
36. Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R et al. Pathologic assessment of the vulnerable human coronary plaque. Heart 2004;90:1385-91.
37. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003;108:1664-72.
38. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-51.
39. Grafe M, Auch-Schwelk W, Zakrzewicz A, Regitz-Zagrosek V, Bartsch P, Graf K et al. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res 1997;81:804-11.
40. Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999;100:1646-52.
41. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002;11:21-30.
42. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999;100:1223-9.
43. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 2013;19:1166-72.
44. Beyazit Y, Purnak T, Guven GS, Haznedaroglu IC. Local bone marrow Renin-Angiotensin system and atherosclerosis. Cardiol Res Pract 2010;2011:714515.
45. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998;83:952-9.
46. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999;84:695-703.
47. Sahar S, Dwarakanath RS, Reddy MA, Lanting L, Todorov I, Natarajan R. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res 2005;96:1064-71.
48. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K et al. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999;17:537-45.
49. Rafatian N, Milne RW, Leenen FH, Whitman SC. Role of renin-angiotensin system in activation of macrophages by modified lipoproteins. Am J Physiol Heart Circ Physiol 2013;305:H1309-20.
50. Ramaha A, Patston PA. Release and degradation of angiotensin I and angiotensin II from angiotensinogen by neutrophil serine proteinases. Arch Biochem Biophys 2002;397:77-83.
51. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-90.
52. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavassiliou VG. Inflammation and atherosclerosis. Eur J Vasc Endovasc Surg 2006;31:386-93.
53. Takata H, Yamada H, Kawahito H, Kishida S, Irie D, Kato T et al. Vascular angiotensin II type 2 receptor attenuates atherosclerosis via a kinin/NO-dependent mechanism. J Renin Angiotensin Aldosterone Syst 2013; doi: 10.1177/1470320313491794.
54. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, Bader M et al. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension 2008;51:1352-7.
55. Ignjacev-Lazich I, Kintsurashvili E, Johns C, Vitseva O, Duka A, Shenouda S et al. Angiotensin-converting enzyme regulates bradykinin receptor gene expression. Am J Physiol Heart Circ Physiol 2005;289:H1814-20.
56. da Cunha V, Martin-McNulty B, Vincelette J, Choy DF, Li WW, Schroeder M et al. Angiotensin II induces histomorphologic features of unstable plaque in a murine model of accelerated atherosclerosis. J Vasc Surg 2006;44:364-71.
57. Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 2006;113:2744-53.
58. Jin SX, Shen LH, Nie P, Yuan W, Hu LH, Li DD et al. Endogenous renovascular hypertension combined with low shear stress induces plaque rupture in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2012;32:2372-9.
59. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991;11:1223-30.
60. Hansson GK, Hellstrand M, Rymo L, Rubbia L, Gabbiani G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989;170:1595-608.
61. Lin J, Kakkar V, Lu X. Impact of matrix metalloproteinases on atherosclerosis. Curr Drug Targets 2014;15:442-53.
62. Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med 1998;3:199-206.
63. Cheng C, Tempel D, van Haperen R, van Damme L, Algur M, Krams R et al. Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype. Atherosclerosis 2009;204:26-33.
64. Wang M, Zhang J, Spinetti G, Jiang LQ, Monticone R, Zhao D et al. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol 2005;167:1429-42.
65. -/- mice. Arterioscler Thromb Vasc Biol 2012;32:1453-9.
66. Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004;109:1482-8.
67. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995;95:2266-74.
68. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 1996;149:367-80.
69. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006;12:1075-80.
70. Stoneman VE, Bennett MR. Role of apoptosis in atherosclerosis and its therapeutic implications. Clin Sci (Lond) 2004;107:343-54.
71. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000;52:639-72.
72. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide. Circ Res 1997;81:970-6.
73. Li D, Yang B, Philips MI, Mehta JL. Proapoptotic effects of ANG II in human coronary artery endothelial cells: role of AT1 receptor and PKC activation. Am J Physiol 1999;276(3 Pt 2):H786-92.
74. Lyngso C, Erikstrup N, Hansen JL. Functional interactions between 7TM receptors in the renin-angiotensin system-dimerization or crosstalk? Mol Cell Endocrinol 2009;302:203-12.
75. Greene AS, Amaral SL. Microvascular angiogenesis and the renin-angiotensin system. Curr Hypertens Rep 2002;4:56-62.
76. Mofidi R, Crotty TB, McCarthy P, Sheehan SJ, Mehigan D, Keaveny TV. Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease. Br J Surg 2001;88:945-50.
77. Kaminska M, Mogielnicki A, Stankiewicz A, Kramkowski K, Domaniewski T, Buczko W et al. Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats. J Physiol Pharmacol 2005;56:571-85.
78. Breitenstein A, Tanner FC, Luscher TF. Tissue factor and cardiovascular disease: quo vadis? Circ J 2010;74:3-12.
79. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005;3:1879-83.
80. Viles-Gonzalez JF, Fuster V, Badimon JJ. Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med 2006;6:489-99.
81. Celi A, Cianchetti S, Dell'Omo G, Pedrinelli R. Angiotensin II, tissue factor and the thrombotic paradox of hypertension. Expert Rev Cardiovasc Ther 2010;8:1723-9.
82. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995;95:1353-62.
83. van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994;90:362-8.
84. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
85. Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000;86:139-43.
86. Koh KK, Chung WJ, Ahn JY, Han SH, Kang WC, Seo YH et al. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 2004;177:155-60.
87. Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol 2008;295:H1377-84.
88. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2010;30:1606-13.
89. Yang JM, Dong M, Meng X, Zhao YX, Yang XY, Liu XL et al. Angiotensin-(1-7) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells. Arterioscler Thromb Vasc Biol 2013;33:1978-85.
90. Zhang C, Zhao YX, Zhang YH, Zhu L, Deng BP, Zhou ZL et al. Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc Natl Acad Sci U S A 2010;107:15886-91.
91. Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM et al. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension 2008;51:574-80.
92. Peiro C, Vallejo S, Gembardt F, Azcutia V, Heringer-Walther S, Rodriguez-Manas L et al. Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. J Hypertens 2007;25:2421-5.
93. Faria-Silva R, Duarte FV, Santos RA. Short-term angiotensin(1-7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension 2005;46:948-52.
94. Rentzsch B, Todiras M, Iliescu R, Popova E, Campos LA, Oliveira ML et al. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 2008;52:967-73.
95. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV et al. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol 2010;185:5569-76.
96. Guo YJ, Li WH, Wu R, Xie Q, Cui LQ. ACE2 overexpression inhibits angiotensin II-induced monocyte chemoattractant protein-1 expression in macrophages. Arch Med Res 2008;39:149-54.
97. Souza LL, Costa-Neto CM. Angiotensin-(1-7) decreases LPS-induced inflammatory response in macrophages. J Cell Physiol 2012;227:2117-22.
98. Thomas MC, Pickering RJ, Tsorotes D, Koitka A, Sheehy K, Bernardi S et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 2010;107:888-97.
99. Zhang F, Ren J, Chan K, Chen H. Angiotensin-(1-7) regulates Angiotensin II-induced VCAM-1 expression on vascular endothelial cells. Biochem Biophys Res Commun 2013;430:642-6.
100. Wang L, Hu X, Zhang W, Tian F. Angiotensin (1-7) ameliorates angiotensin II-induced inflammation by inhibiting LOX-1 expression. Inflamm Res 2013;62:219-28.
101. Fraga-Silva RA, Costa-Fraga FP, De Sousa FB, Alenina N, Bader M, Sinisterra RD et al. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics (Sao Paulo) 2011;66:837-41.
102. Fraga-Silva RA, Savergnini SQ, Montecucco F, Nencioni A, Caffa I, Soncini D et al. Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. Thromb Haemost 2014;111:736-47.
103. Dong B, Zhang C, Feng JB, Zhao YX, Li SY, Yang YP et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:1270-6.
104. Toton-Zuranska J, Gajda M, Pyka-Fosciak G, Kus K, Pawlowska M, Niepsuj A et al. AVE 0991-angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2010;61:181-3.
105. Wang Y, Tikellis C, Thomas MC, Golledge J. Angiotensin converting enzyme 2 and atherosclerosis. Atherosclerosis 2013;226:3-8.
106. -/- mice. Arterioscler Thromb Vasc Biol 2011;31:758-65.
107. Jilma B, Li-Saw-Hee FL, Wagner OF, Beevers DG, Lip GY. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci (Lond) 2002;103:131-6.
108. Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm 2009;2009:752406.
109. Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004;44:362-8.
110. Artom N, Montecucco F, Mach F, Dallegri F, Pende A. Angiotensin II receptor antagonists in acute coronary syndromes. Eur J Clin Invest 2014;44:219-30.
111. Trevelyan J, Brull DJ, Needham EW, Montgomery HE, Morris A, Mattu RK. Effect of enalapril and losartan on cytokines in patients with stable angina pectoris awaiting coronary artery bypass grafting and their interaction with polymorphisms in the interleukin-6 gene. Am J Cardiol 2004;94:564-9.
112. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 2003;163:1155-64.
113. Di Napoli M, Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003;34:2922-9.
114. Chen HQ, Tan HY, Yang YW, Qiu L, Liu XQ. Effects of ramipril on serum monocyte chemoattractant protein 1, interleukin-18, and interleukin-10 in elderly patients with acute coronary syndrome. Heart Vessels 2010;25:77-81.
115. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
116. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
117. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
118. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
119. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-63.
120. O'Keefe JH, Lurk JT, Kahatapitiya RC, Haskin JA. The renin-angiotensin-aldosterone system as a target in coronary disease. Curr Atheroscler Rep 2003;5:124-30.
121. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
122. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.
123. McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006;47:726-33.
124. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
125. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011;342:d2234.
126. Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013;61:131-42.
127. Sorbets E, Labreuche J, Simon T, Delorme L, Danchin N, Amarenco P et al. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. Eur Heart J 2014;35:1760-8.
128. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17.
129. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-54.
130. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004;109:8-13.
131. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 2003;140:809-24.
132. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
133. von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 2014;144:41-9.
134. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
135. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010;160:1273-92.
136. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007;25:951-8.
137. Demacq C, Metzger IF, Gerlach RF, Tanus-Santos JE. Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers. Clin Chim Acta 2008;394:72-6.
138. Eberhardt W, Beeg T, Beck KF, Walpen S, Gauer S, Bohles H et al. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int 2000;57:59-69.
139. Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin Chim Acta 2010;411:1875-82.
140. Campbell DJ, Zeitz CJ, Esler MD, Horowitz JD. Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens 2004;22:1971-6.
141. Legedz L, Randon J, Sessa C, Baguet JP, Feugier P, Cerutti C et al. Cathepsin G is associated with atheroma formation in human carotid artery. J Hypertens 2004;22:157-66.
142. MaassenVanDenBrink A, de Vries R, Saxena PR, Schalekamp MA, Danser AH. Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc Res 1999;44:407-15.
143. Uehara Y, Miura S, Yahiro E, Saku K. Non-ACE pathway-induced angiotensin II production. Curr Pharm Des 2013;19:3054-9.
144. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7.
145. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 2009;15:565-71.
146. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996;14:799-805.
147. Ortiz-Perez JT, Riera M, Bosch X, De Caralt TM, Perea RJ, Pascual J et al. Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. PLoS ONE 2013;8:e61695.
148. Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 2008;585:303-12.
149. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 2008;52:750-4.